[Comment] The arrival of antibody drug conjugates in nasopharyngeal cancer

Nasopharyngeal cancer has long been known for its high sensitivity to chemotherapy.1 In the first randomised phase 3 trial reported in recurrent or metastatic nasopharyngeal cancer,2 the combination of cisplatin and gemcitabine was established as the standard first-line chemotherapy after resulting in superior overall survival than the comparator cisplatin and 5-fluorouracil.3,4